Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
详细信息 查看全文
- 作者：Michel Farniera ; michelfarnier@nerim.net" class="auth_mail" title="E-mail the corresponding author ; Peter Jonesb ; Randall Severancec ; Maurizio Avernad ; Elisabeth Steinhagen-Thiessene ; Helen M. Colhounf ; Yunling Dug ; Corinne Hanotinh ; Stephen Donahueg
- 关键词：Alirocumab ; Ezetimibe ; Low-density lipoprotein cholesterol ; Monoclonal antibody ; PCSK9 ; Rosuvastatin
- 刊名：Atherosclerosis
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：244
- 期：Complete
- 页码：138-146
- 全文大小：715 K
文摘
- •
Many high CV risk patients do not achieve their LDL–C goal on current therapies.
- •
Adding alirocumab to rosuvastatin reduced LDL–C more than other therapeutic options.
- •
Alirocumab 75 mg and 150 mg Q2W dosing regimens allow a treat-to-target approach.